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 !#= * .  
-) "!  D-:/U  ,#* !# !# ! 
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/! #  3> 
"=C 5/1 A M K	;! D# <!#)  # 
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 -
	
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! PCR #)  "! /C ) 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3', nucleotides 4219-4196 (  
N! )#!#B !# #x; 5g	F( !!  =! 
3 ])bp 935(D X& #!#B G1 + G2[   
=! 3 ])bp 532(D X& #!#B G1 + G3[  , - 
 
 )16.(   
)#+!B Vd; #$	#; 5	M - #" 	:  
	$!	;
 -/!   94 -& +
$  !#= 
- 5 2 D-2L s_$ 35 -7# * 20  -
6  
 94 -& +
$  D!#= X& 	&   *  - 
5 30 -
6   60 -& +
$  D!#=   
60  -
6   68 -& +
$  D!#=   
-A#  	9 * %
 - 5 7 -2L    
68 -& +
$  !#=.  
N! !#   #[  -  /	;  5g	F( PCR  -
3	9 bp 935 !# DNA) A  =! 3   -
3	9 bp 532 !# DNA )  L   =! 3  * .
5g	F( PCR #  3> "=C 5/1  M
A K	;! # "	 #+/!   #=  <"!
! 
C ) "! 8#9 -02  DNA ladder 3	9 - 
 5:ULbp 100 NI; <" * . !#  #)n  #, 
)
  !&  <*  "! "=C 3>   <G+$ 3> 
 N+	,!)BioRadm, USA( <X+$! *.  
 /C N+*! ^0A # !# ! )E3 (+) GHR  
E3 (-) GHR  /C !# o	G"	) <#= -$ 
 :.9] /C  !!E3 (+) GHR[ o	G"#+) D
] /C  !!E3 (+) GHR  /C   
E3 (-) GHR [ PmA !! /C !# o	G"	) 
] /C  !!E3 (-) GHR [ 
*  V02; .
/C 
!!#   d+
! 	 )-)     
  !# !
 V/$   !# !  3:; "! <X+$! 
Hardy–Weinberg * -.$(.  
! ,	= K#$  /A +*
   S  ,	= 
"!0,! "!0,!#B N:; #= .!   #B
_/  $eB  /A  +*
   S  ;
C 
#/, , "! <X+$!   #+  ]	# ) ) oB 
 E#, D	"C ( <"!
! #=  *.  !hsCRP  
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>? )  =!3 <
#=  * 		) -A# !# !   1B  	 
  !  
  <* 	2; #+	;	
	! S "! <X+$!
 ]	# ,  s;g)oB  E#, D	"C(  1[$
#=.  ,	= S  
 $eB ,	= !
 ]	# ,  "!0,!)oB  E#, D	"C ( N:;
* .! HbA1c 3	.= #L )   "! <X+$!  
S !
+$!  !#=	;#, T  />   
)Gel exclusion chromatography) (oB  D	"C
E#, (1[$ * . N! S !!  -)   ! "! 
r(/ MF+7!  (M $!  $C  #2 - 
- #M 
  *.  
<! K#
 ,  )  C ! !SPSS -I0
  16 
)version 16, SPSS Inc., Chicago, IL ( 	
 5	M -   #= !#L (;  -[;  
 NG
±  #= S!= M  : P!#(
! .

!!#  5X; $# !#  "! !# ! N _;	
> )




> <#= -$ N)ANOVA (
* <X+$! .: lU$  A  C !05/0 < P 
* -+ #= #d




 3&  -:/U (; !# ! / 5FI1 
$! <* <! 
.  <) -, 	9 )
  !	 ! D	*  "$#U7  !# !  /	+
-A# 1B   $! )* !# ! "! #+.  
  
  
 1 .   ! "#$% & '(   " '")   
 *+ ,+ -. /0  '$0 1)1+DNA ladder /0. 
'$0 -( *+ ,+  *+ 2+ 1)  1)Exon 3 (+/+) 
GHR 3Exon 3 (-/-) GHR  Exon 3 (+/-) GHR 4 1+.  
  
 51 .*2%16 /! 7# 4
%1+ 81 9:  
   	 )40 (    
	)40 (   P 
' )( 68/11 ± 78/55  30/8 ± 96/56 56/0  
! ]/#)([ )80(32   )87(35   40/0 
1# 23
 4  5)BMI) (2kg/m( 3/2 ± 79/25 7/0 ± 9/25 48/0 
617 )mmol/l(  6/0 ± 1/5  4/0 ± 8/4  51/0  
$!86 )mg/dl( 3/36 ± 9/192 0/47 ± 8/178 07/0 
4!#  9!8"7)TG) (mg/dl( 4/80 ± 9/159 3/97 ± 4/147 08/0 
LDL )mg/dl( 8/23 ± 4/109 5/25 ± 7/96 01/0 
HDL )mg/dl( 5/9 ± 4/44 5/4 ± 5/42 12/0 
hsCRP )mg/l( 7/1 ± 9/4 3/1 ± 9/2 01/0 
HbA1c )( 6/0 ± 8/5  2/0 ± 7/4 02/0  
<!  NG
 ^0A# )± $! <*  : P!#(
!.   
LDL: -+0
!  NO;#B	_/  ZNB   HDL :-+0
!  NO;#B	_/ Zg   
hsCRP : 3:  NO;#BC  Zg $0A   HbA1c :-"	= N	=	)  
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>? )  =!3 <
#=  * 		)  -A# !# !  1B  	 
  !  
 52 . 4#)4<= ( '>& -(3 &  " '") )Exon 3 GHR.(  
   	 )40 (   
	 )40 (   P  
Exon 3 (+/+) GHR  )5/62(25  )0/10(4  0001/0 <  
exon 3 (+/-) GHR  )5/17(7  )0/40(16  0003/0   
exon 3 (-/-) GHR  )0/20(8  )0/50(20  0005/0 <  
Exon 3 (+/+) GHR : =! !! 5	G"	) ?;	
>3 <
#=  Z* 		) Exon 3 (+/-) GHR : =! L  5	G"#+) ?;	
>3 Z  
Exon 3 (-/-) GHR : =! L  5	G"	) ?;	
>3 <
#= * 		) .   
  
 53 .@ *=A1B 106C -( D+ E%+1$ 7#  "7 F$9 1)  
	  
  !  
)80(  
Exon 3 (+/+) 
GHR  
)29 (  
Exon 3 (+/-) 
GHR  
)23 (  
Exon 3 (-/-) 
GHR  
)28 (  
 P 
' )( 99/9 ± 37/56 39/8 ± 96/55 33/7 ± 89/55 81/3 ± 24/56 68/0  
! ]/#)([  )84(67 )79(23  )82(19 )86(25 43/0 
1# 23
 4  5)BMI) (2kg/m(  50/1 ± 85/25 68/3 ± 56/26 41/2 ± 98/25 41/0 ± 01/25 20/0 
617 )mmol/l(  33/0 ± 95/4 62/0 ± 95/5 24/0 ± 65/4 34/0 ± 32/4 02/0  
$!86 )mg/dl(  53/37 ± 85/185 35/45 ± 62/198 37/57 ± 98/189 13/13 ± 23/169 03/0  
4!#  9!8"7)TG) (mg/dl(  85/88 ± 65/153 55/91 ± 85/176 33/78 ± 63/159 46/81 ± 71/124 01/0  
LDL )mg/dl( 65/24 ± 05/103 05/34 ± 25/114 22/27 ± 35/109 26/12 ± 27/86 01/0  
HDL )mg/dl( 71/5 ± 45/43 11/6 ± 15/39 66/3 ± 35/44 06/4 ± 16/47 04/0  
hsCRP )mg/l( 40/1 ± 90/3 60/0 ± 60/4 90/0 ± 20/4 20/1 ± 60/3 12/0 
HbA1c )( 51/0 ± 25/5 71/0 ± 07/6 44/0 ± 57/5 01/1 ± 14/4 02/0  
<!  NG
 ^0A# )± $! <*  : P!#(
!.  
LDL: -+0
!  NO;#B	_/  ZNB HDL :-+0
!  NO;#B	_/  Zg hsCRP : 3:  NO;#BC  Zg $0A HbA1c :-"	= N	=	)  
  
 5:UL "	 #+/!DNA  /C <
#= > ) 
 ?;	
> 	& D* 		)Exon 3 (+/+) GHR D
Exon 3 (-/-) GHR  Exon 3 (+/-) GHR  
 !
 !) *1.(  -dAe  ? ;	
> -, 	* )
 5	G"	)Exon 3 (+/+) GHR DExon 3 (-/-) GHR 
 5	G"#+) ?;	
>  
  !! K!, #)
Exon 3 (+/-) GHR  !! 3>  # 
 
$! "=C.   
 3&  )*   !# ! _;	
> 
!!# 2 
$! <* <! 




  3:; "! D)* !# !  ! <#=Hardy–
Weinberg   # B  #,)25/0  =P D18/0  =P D
21/0  =P .( -, $! hI 3&  
!!# 
 =! !! 5	G"	) ?;	
>3 <
#=  
 * 		)]Exon 3 (+/+) GHR [  !# ! 
: 	9 -   Z$! <	 #+ )* !# ! "! !
?;	
> 
!!#  -, /A  N)  5	G"#+) )
 =! L  5	G"	) 	93  <
#= N!  
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  !  
]Exon 3 (+/-) GHR  Exon 3 (-/-) GHR[ - D
$!  !# ! "! #+ )* !# !  ^;#;.  
!	 -02 "$#U7  ^0A # /	+
?;	
>  -, ! 
 !# ! ,   }+I )
< C   /C A !# !  )Exon 3 (-) GHR  -
V 	9  1), #=   :p N!  
 ?;	
>  !# !Exon 3 (-/-) GHR  	% #+
 $!) 3&3(.  
&'  
 
!!#  -, #= hI -:/U N! 
?;	
>  <
#= =! PmA A ) 		) 
 <~ - D* =! L  5	G"	) ?;	
>3  DC
 :Exon 3 (-/-) GHR 0 V/$ )* !# !  D
  !# ! "! #+-A# 1B   $! .
  !	 ! $# KG) DN q) "$#U7 
 hI D!# ! ,   - ]	# /	+
 !	 N! ! -, #=  "$#U7  !! !# ! 
 =! L  ?;	
>3 5	G"	) ?;	
> <~ - D
 : 	9 - DC ?;	
>  !# ! - .0
 !
  =! !! 5	G"	)3 : D  
Exon 3 (+/+) GHRNB D $! #; . 
!!# 
?;	
>  =! L  )3  -:/U 	 !# ! , 
 82(; N! 63  N! 
!!#   -, 	 M
V) #G 5:/U  ?;	
>  ! 
!	7)21-19.(  
 =! L  ?;	
> N  ] .;!3 < 
#=  
!	  * 		) "$#U7  !  /	+
 $! -+ #= !#L -:/U 	 X+I . -:/U  
Gao  =! L  /C +d ( #6! D!) 3  >
<
#=  C NB  * 		) BMI 1), D
 K$ 1), D-[+
   N/	0
! - 2 !
 k  " - p! !! ,	,  /	+
#= S!= $! <)22 .( +d ( #6! DNq)
  N/	0
! l*#; ! ! 1! !  /C N!
 $! <* <) V/$ 
!	&	
  ,	,)16 .( "!
!	 ! 1), Dr(/ N! "$#U7   /	+
 =! L  !# !3  <
#= >  * 		) 
-:/U 1B 5:/U +
    U -+X= ! 2 .
 =! L  /C /	+ )!3  #+ 
"
 !  # -:/U   -, #= hI
 L  /C !! !# ! -, * 6 /G#,C - e+.
 =!3 DBMI NB  .0
 #+% ,	= (;  #;
 
! /C N! &! !# ! -)23  .(  
-:/U  Strawbridge )  -, ! 
 !
 =! L  ?;	
> !# +$	G"	)3  <
#= 
1B 5!#6! !! D* 		)   #!#  -
!#=
 	
2  $!)10 .(V 1),  !	 #=  "$#U7 
 5	G"	) ?;	
>  !# !  <~ - D/	+
 =! L 3  <
#= -:/U  * 		)  





 =! L  /C 
!!#  1),3  !# ! 
-A# 1B   -:/U   $! N #pA 

 <)  +d ( 5!#6! "! f: -, * N! 
 	
  2 2  	& - ]	# $! N
* /C N! .!	 * 1), "$#U7  /	+
 	
 2  L  5	G"	) ?;	
>  !# ! 
 =!3 <
#= -:/U  * 		)   D#pA 
$! ^U N! # #+ R; . #d
   -+./!
!	 1! ! -, *! "$#U7  !# !  /	+
-A# 1B    - e+! !:+$! "! -

  %;
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>? )  =!3 <
#=  * 		)  -A# !# !  1B  	 
  !  
 	
 2  N!  
 #G :+ !	  $!
 ! N  D-, C <~ - Z+0) 7 #!
-A# 1B   ?;	
> !! !:;  L  )
 =!3 <
#=  N!  / 
	 
 * 		) 
  	&-A# 1B   
	 . "! - C
-+  # -:/U N! ) C /C 	& -, 0! 
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Abstract 
Background: Metabolic impacts of two important alleles of the growth hormone receptors (GHR), 
one with retention of exon 3 [exon 3 (+) GHR] and the other with the deletion of it [exon 3 (-) GHR], 
on the metabolic risk factors of type 2 diabetes mellitus (T2DM) are really unknown. We aimed to 
evaluate relationships between the genotypes and metabolic risk factors of T2DM.  
Methods: In the present study, 40 patients in pre-diabetic state and 40 healthy subjects were selected 
based on their clinical and laboratory evidence. For genotyping, DNA was extracted from the 
leukocytes of peripheral blood and amplified by multiplex polymerase chain reaction method. 
Genotypes of the amplified DNA samples were resolved using 1.5% agarose gel electrophoresis. 
Other risk factors were also determined by using standard methods and appropriate kits. 
Findings: Frequency of the homozygote exon 3 retained genotype [exon 3 (+/+) GHR] was significantly 
higher in the subject in pre-diabetic state (P < 0.001); the frequency of exon 3 (+/-) GHR and exon 3 (-/-) 
GHR genotypes were significantly higher in the control subjects (P < 0.001). The decrease of metabolic 
risk factors was profound in subjects with exon 3(-/-) GHR genotype (P < 0.001). 
Conclusion: The presence of exon 3 deleted allele of GHR, especially in the homozygosity situation, 
was associated with decreased levels of the metabolic risk factors of type 2 diabetes mellitus. So, the 
exon 3 deleted GHR may have more robust biological and metabolic activities lead to the resistance 
against T2DM. 
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